Earnings ·
Phio Pharmaceuticals Corp. reported financial results for the quarter ended June 30, 2026, on August 6, 2026
PHIOPhio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. reported financial results for the quarter ended June 30, 2026, on August 6, 2026. The company incurred a net loss of $4.1 million and held cash reserves of $13.0 million as of June 30, 2026. Research and development expenses rose to $3.1 million for the quarter, driven by increased nonclinical toxicology and CMC costs associated with its lead candidate PH-762. The company announced strategic advancements including the initiation of commercial scale active pharmaceutical ingredient production and a long-term non-clinical toxicology study expected to complete by year-end. Additionally, Phio plans to request an FDA meeting in Q3 2026 regarding next steps for PH-762 development and appointed Dr. R. Todd Plott M.D. to its Board of Directors. The company operates as a clinical-stage biopharmaceutical firm developing siRNA gene silencing therapeutics for cancer treatment.